Biblio
Export 159 results:
[ Author] Title Type Year Filters: First Letter Of Last Name is G [Clear All Filters]
“White Matter Degradation is Associated with Reduced Financial Capacity in Mild Cognitive Impairment and Alzheimer's Disease.”, J Alzheimers Dis, vol. 60, no. 2, pp. 537-547, 2017.
, “Clinical Application of Automatic Segmentation of Medial Temporal Lobe Subregions in Prodromal and Dementia-Level Alzheimer's Disease.”, J Alzheimers Dis, vol. 54, no. 3, pp. 1027-1037, 2016.
, “Cerebrospinal Fluid Aβ42/Aβ40 as a Means to Limiting Tube- and Storage-Dependent Pre-Analytical Variability in Clinical Setting.”, J Alzheimers Dis, vol. 57, no. 2, pp. 437-445, 2017.
, “Innovative Biomarkers for Alzheimer's Disease: Focus on the Hidden Disease Biomarkers.”, J Alzheimers Dis, vol. 62, no. 4, pp. 1507-1518, 2018.
, “The Existence of Primary Age-Related Tauopathy Suggests that not all the Cases with Early Braak Stages of Neurofibrillary Pathology are Alzheimer's Disease.”, J Alzheimers Dis, 2015.
, “The First Historically Reported Italian Family with FTD/ALS Teaches a Lesson on C9orf72 RE: Clinical Heterogeneity and Oligogenic Inheritance.”, J Alzheimers Dis, vol. 62, no. 2, pp. 687-697, 2018.
, “Exploring the Role of Cognitive Factors in a New Instrument for Elders' Financial Capacity Assessment.”, J Alzheimers Dis, vol. 62, no. 4, pp. 1579-1594, 2018.
, “Antibodies to Signaling Molecules and Receptors in Alzheimer's Disease are Associated with Psychomotor Slowing, Depression, and Poor Visuospatial Function.”, J Alzheimers Dis, vol. 59, no. 3, pp. 929-939, 2017.
, “Kynurenine Pathway Metabolites in Alzheimer's Disease.”, J Alzheimers Dis, vol. 60, no. 2, pp. 495-504, 2017.
, “Antibodies to Multiple Receptors are Associated with Neuropsychiatric Symptoms and Mortality in Alzheimer's Disease: A Longitudinal Study.”, J Alzheimers Dis, vol. 64, no. 3, pp. 761-774, 2018.
, “Argyrophilic Grain Pathology in Frontotemporal Lobar Degeneration: Demographic, Clinical, Neuropathological, and Genetic Features.”, J Alzheimers Dis, vol. 63, no. 3, pp. 1109-1117, 2018.
, “Alzheimer's Disease and Face Masks in Times of COVID-19.”, J Alzheimers Dis, vol. 79, no. 1, pp. 9-14, 2021.
, “Association between Peripheral Leptin and Adiponectin Levels and Cognitive Decline in Patients with Neurocognitive Disorders ≥65 Years.”, J Alzheimers Dis, vol. 66, no. 3, pp. 1255-1264, 2018.
, “Using Machine Learning to Predict Dementia from Neuropsychiatric Symptom and Neuroimaging Data.”, J Alzheimers Dis, vol. 75, no. 1, pp. 277-288, 2020.
, “Impact of a Virtual Dementia Experience on Medical and Pharmacy Students' Knowledge and Attitudes Toward People with Dementia: A Controlled Study.”, J Alzheimers Dis, vol. 62, no. 2, pp. 867-876, 2018.
, “Memory impairment in transgenic Alzheimer mice requires cellular prion protein.”, J Neurosci, vol. 30, no. 18, pp. 6367-74, 2010.
, “Cognitive Outcomes in Autosomal-Dominant Alzheimer's Disease: A Comprehensive Review from a Colombian Kindred with the Presenilin-1 E280A Mutation.”, J Alzheimers Dis, vol. 101, no. 2, pp. 397-415, 2024.
, “Current and Future Prevalence Estimates of Mild Cognitive Impairment, Dementia, and Its Subtypes in a Population-Based Sample of People 70 Years and Older in Norway: The HUNT Study.”, J Alzheimers Dis, vol. 79, no. 3, pp. 1213-1226, 2021.
, “Cognitive Effects of Soy Isoflavones in Patients with Alzheimer's Disease.”, J Alzheimers Dis, vol. 47, no. 4, pp. 1009-19, 2015.
, “Cognitive Variability Predicts Incident Alzheimer's Disease and Mild Cognitive Impairment Comparable to a Cerebrospinal Fluid Biomarker.”, J Alzheimers Dis, vol. 61, no. 1, pp. 79-89, 2018.
, “The Multiple Object Test as a Performance Based Tool to Assess Cognitive Driven Activity of Daily Living Function in Parkinson's Disease.”, J Alzheimers Dis, vol. 53, no. 4, pp. 1475-84, 2016.
, “Shape-Attributes of Brain Structures as Biomarkers for Alzheimer's Disease.”, J Alzheimers Dis, vol. 56, no. 1, pp. 287-295, 2017.
, “Characteristics of Alzheimer's Disease Patients with Severe Executive Disorders.”, J Alzheimers Dis, vol. 51, no. 3, pp. 815-25, 2016.
, “Dynamics of Frailty and Cognition After Age 50: Why It Matters that Cognitive Decline is Mostly Seen in Old Age.”, J Alzheimers Dis, vol. 58, no. 1, pp. 231-242, 2017.
, “Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift.”, Neuron, vol. 69, no. 2, pp. 203-13, 2011.
,